Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis
Background: A systematic review and meta-analysis was conducted to assess breast cancer (BC) outcomes among patients with early-stage hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) BC, receiving adjuvant endocrine therapy. Methods: Randomized controlled tr...
Main Authors: | Elizabeth M. Salvo, Abril Oliva Ramirez, Jenilee Cueto, Ernest H. Law, Aaron Situ, Chris Cameron, Imtiaz A. Samjoo |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-06-01
|
Series: | Breast |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977621000230 |
Similar Items
-
Fear of cancer recurrence in South Korean survivors of breast cancer who have received adjuvant endocrine therapy: a cross-sectional study
by: Seul Ki Park, et al.
Published: (2023-07-01) -
Estimating the overall survival benefit of adjuvant chemo‐endocrine therapy in women over age 50 with pT1‐2N0 early stage breast cancer and 21‐gene recurrence score ≥26: A National Cancer Database analysis
by: Nickolas Stabellini, et al.
Published: (2023-10-01) -
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
by: Julia Foldi, et al.
Published: (2023-06-01) -
Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials
by: Hong-Fei Gao, et al.
Published: (2021-10-01) -
Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy
by: Richard Fischer, et al.
Published: (2012-01-01)